Observational Study
Copyright ©The Author(s) 2021.
World J Clin Oncol. Mar 24, 2021; 12(3): 183-194
Published online Mar 24, 2021. doi: 10.5306/wjco.v12.i3.183
Table 4 Patients with testicular germ cell tumors who underwent cisplatin-based chemotherapy and experienced a thromboembolic event in the literature
Number of patients
Percentage of patients with TE
Main findings
Piketty et al[9], 2005100 patients with GCT; 100 controls with various neoplasms19 (19%)> All stages of TGCT;
> TE: 1st day of chemo to 6 mo after;
> Of 19 TEE, 14 occurred during chemotherapy, 5 after chemo;
> Risk factors for TEE: High body surface area, elevated serum LDH
Honecker et al[6], 201319322 (11%)> All stages of TGCT;
> TEE: Considered therapy-associated if occurred from start of chemotherapy to 6 wk after;
> 18 (%) TEE occurred before chemotherapy;
> Risk factors for TEE: Pure seminoma, retroperitoneal or supraclavicular lymph node metastases, elevated LDH, CVC
Bezan et al[18], 201765734 (5.2%)> All stages of TGCT;
> TEE: During 1st year of follow-up;
> Risk factors for TEE: Higher clinical stage and RPLN, increased number of cycles of chemotherapy
Tran et al[19], 20191135150 (10%)> Metastatic TGCT;
> TEE: During or within 90 d of chemotherapy;
> Risk factors for TEE: Large RPLN, CVC
Paffenholz et al[16], 201922549 (19%)> All stages of TGCT;
> TEE: Start of chemotherapy to 6 mo after;
> Risk factors for TEE: Higher clinical stage, elevated serum LDH, febrile neutropenia, CVC;
> Patients with TEE had significantly reduced overall survival during median follow-up of 8 mo
Current Study, 20206818 (26.5%)> All stages of TCGT;
> TEE: Following orchiectomy;
> Risk factors for TEE: Higher pathologic stage, greater number of chemotherapy cycles